publications-banner

Information about pipeline products

PublicationView

Edoxaban
Cardiovascular - AF
Patient outcomes in very elderly patients with non-valvular atrial fibrillation - ANAFIE Registry -
Suzuki S, Yamashita T, Akao M, et al.
Circ Rep. 2024;6(8):283-293. doi: 10.1253/circrep.CR-24-0061.
Edoxaban
Lung Cancer Cardiovascular - AF
Venous thromboembolism in patients undergoing surgery for lung cancer: A post hoc analysis of the Cancer-VTE Registry
Kawachi R, Okano T, Awano N, et al.
Jpn J Clin Oncol. 2024:hyae090. doi: 10.1093/jjco/hyae090. Epub ahead of print.
Pexidartinib
Other/Multi Tumor-agnostic
TURALIO® Risk Evaluation and Mitigation Strategy Program (tREMS): 3-year retrospective hepatic safety assessment
Dharmani C, Fofah O, Fallon M, et al.
Future Oncol. 2024. doi: 10.1080/14796694.2024.2373687.
Edoxaban
Cardiovascular - AF
Risk factors of ischemic stroke in patients with atrial fibrillation after transcatheter aortic valve implantation from the randomized ENVISAGE-TAVI AF trial
Hengstenberg C, Unverdorben M, Möllmann H, et al.
Am J Cardiol. 2024;227:98-104. doi: 10.1016/j.amjcard.2024.07.019. Epub ahead of print.
Edoxaban
Cardiovascular - AF
Clinical effects of direct oral anticoagulants in elderly patients with a bioprosthetic valve and atrial fibrillation
Amano M, Takegami M, Miyake M, et al.
Int J Cardiol. 2024;413:132375. doi: 10.1016/j.ijcard.2024.132375. Epub ahead of print.
HER3-DXd
Lung Cancer
Cost of early progression: Patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer
Princic N, Marrett E, Kwong Wubghan J, et al.
Future Oncol. 2024. doi: 10.1080/14796694.2024.2370186.
T-DXd
Lung Cancer
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: A plain language summary of the DESTINY-Lung01 study
Smit EF.
Future Oncol. 2024:1-11. doi: 10.1080/14796694.2024.2355724.
HER3-DXd
Breast Cancer
Patritumab deruxtecan in HER2-negative breast cancer: Part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
Brasó-Maristany F, Ferrero-Cafiero JM, Falato C, et al.
Nat Commun. 2024;15(1):5826. doi: 10.1038/s41467-024-50056-y.
Edoxaban
Cardiovascular - AF
Association of D-dimer level with thrombotic events, bleeding, and mortality in Japanese patients with solid tumors: A Cancer-VTE registry subanalysis
Nakamura M, Sakon M, Sasako M, et al.
Int J Clin Oncol. 2024;29:407-416.
Edoxaban
Cardiovascular - AF
Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: Post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial
Zimerman A, Braunwald E, Steffel J, et al.
JAMA Cardiol. 2024:e241793. doi: 10.1001/jamacardio.2024.1793. Epub ahead of print.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer